New tests of blood and spinal fluid can identify people experiencing memory loss from Alzheimer's disease.

An experimental cancer drug that helps the brain turn glucose into energy was able to reverse memory loss in a mouse model of Alzheimer’s disease.

A new generation of blood tests can help diagnose Alzheimer’s disease. But many doctors don’t yet know how to use them.

Early in life, the protein Reelin helps assemble the brain. Later on, it appears to protect the organ from Alzheimer’s and other threats to memory and thinking.

A new generation of blood tests can help doctors diagnose Alzheimer's without a brain scan or spinal tap. But only a few perform as well as traditional tests.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.

The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.